First RNA Therapy Shows Hope for a Rare Motor-Neuron Disease
Nature reports the first RNA therapy success in a rare motor-neuron disease, raising hope for new ALS treatments.
News on dementia, Parkinson’s, multiple sclerosis, stroke, epilepsy and other conditions affecting the brain and nervous system.
Immune Therapy Inside the Body Shows Early Promise Against Multiple Sclerosis
A small trial suggests a modified virus may help the immune system fight multiple sclerosis from inside the body.
Study Links Coffee Metabolism Genes to Parkinson’s Risk Patterns
Study suggests coffee-Parkinson’s links may vary by CYP1A2 genotype in a UK Biobank analysis.
Thousands with Multiple Sclerosis to Get New NHS Walking Therapy
NHS England is rolling out fampridine for multiple sclerosis, aiming to help thousands walk more easily and live more independently.
NHS Rolls Out New Walking Drug for Thousands Living With Multiple Sclerosis
NHS England has launched fampridine for multiple sclerosis, aiming to improve walking and independence for thousands of patients.
BMJ Highlights Pesticide Exposure Link to Higher Motor Neuron Disease Risk
BMJ reports pesticide exposure may raise motor neuron disease risk by 60-70%, highlighting workplace health concerns.
Rett Syndrome Breathing Study Points to New Clue in Rare Neurological Disease
Researchers have identified the cause of abnormal breathing in Rett syndrome, offering a new clue for rare disease care.
NHS Rolls Out Fampridine for Multiple Sclerosis Patients Across England
NHS England has made fampridine routinely available for adults with multiple sclerosis to help improve walking and independence.
Early Alzheimer’s Blood Test Shows Promise for Detecting Symptoms Before They Appear
A new Alzheimer’s blood test may help predict when symptoms are likely to appear, according to the NIH.
NICE updates draft guidance on early Alzheimer’s biomarkers to guide diagnosis pathways
NICE publishes draft guidance proposing validated blood-based biomarkers be integrated into early Alzheimer’s diagnostic pathways, subject to evidence and consultation.
